Cargando…
Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies
In recent years, the excellent curative effect of CD19‐specific chimeric antigen receptor (CAR) T‐cell therapy has brought hope to patients with relapsing or refractory B‐cell hematological malignancies, however relapse after CAR T‐cell infusion has hindered the widespread clinical application of th...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019219/ https://www.ncbi.nlm.nih.gov/pubmed/33416209 http://dx.doi.org/10.1111/cas.14799 |
_version_ | 1783674334683856896 |
---|---|
author | Guo, Zhenling Tu, Sanfang Yu, Siyao Wu, Liufang Pan, Wanying Chang, Ning Zhou, Xuan Song, Chaoyang Li, Yuhua He, Yanjie |
author_facet | Guo, Zhenling Tu, Sanfang Yu, Siyao Wu, Liufang Pan, Wanying Chang, Ning Zhou, Xuan Song, Chaoyang Li, Yuhua He, Yanjie |
author_sort | Guo, Zhenling |
collection | PubMed |
description | In recent years, the excellent curative effect of CD19‐specific chimeric antigen receptor (CAR) T‐cell therapy has brought hope to patients with relapsing or refractory B‐cell hematological malignancies, however relapse after CAR T‐cell infusion has hindered the widespread clinical application of this immunotherapy and targeted antigen‐negative relapse has caused widespread concern. Consequently, strategies for increasing targeted antigens have been created. In addition to the most widely applied target, namely CD19, researchers have further explored the possibility of other targets, such as CD20, CD22, CD33, and CD123, and have tested a series of combination antigen CAR T‐cell therapies. Here, we summarize the current preclinical and clinical studies of dual‐target CAR T cells. |
format | Online Article Text |
id | pubmed-8019219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80192192021-04-08 Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies Guo, Zhenling Tu, Sanfang Yu, Siyao Wu, Liufang Pan, Wanying Chang, Ning Zhou, Xuan Song, Chaoyang Li, Yuhua He, Yanjie Cancer Sci Review Articles In recent years, the excellent curative effect of CD19‐specific chimeric antigen receptor (CAR) T‐cell therapy has brought hope to patients with relapsing or refractory B‐cell hematological malignancies, however relapse after CAR T‐cell infusion has hindered the widespread clinical application of this immunotherapy and targeted antigen‐negative relapse has caused widespread concern. Consequently, strategies for increasing targeted antigens have been created. In addition to the most widely applied target, namely CD19, researchers have further explored the possibility of other targets, such as CD20, CD22, CD33, and CD123, and have tested a series of combination antigen CAR T‐cell therapies. Here, we summarize the current preclinical and clinical studies of dual‐target CAR T cells. John Wiley and Sons Inc. 2021-02-21 2021-04 /pmc/articles/PMC8019219/ /pubmed/33416209 http://dx.doi.org/10.1111/cas.14799 Text en © 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Review Articles Guo, Zhenling Tu, Sanfang Yu, Siyao Wu, Liufang Pan, Wanying Chang, Ning Zhou, Xuan Song, Chaoyang Li, Yuhua He, Yanjie Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies |
title | Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies |
title_full | Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies |
title_fullStr | Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies |
title_full_unstemmed | Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies |
title_short | Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies |
title_sort | preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019219/ https://www.ncbi.nlm.nih.gov/pubmed/33416209 http://dx.doi.org/10.1111/cas.14799 |
work_keys_str_mv | AT guozhenling preclinicalandclinicaladvancesindualtargetchimericantigenreceptortherapyforhematologicalmalignancies AT tusanfang preclinicalandclinicaladvancesindualtargetchimericantigenreceptortherapyforhematologicalmalignancies AT yusiyao preclinicalandclinicaladvancesindualtargetchimericantigenreceptortherapyforhematologicalmalignancies AT wuliufang preclinicalandclinicaladvancesindualtargetchimericantigenreceptortherapyforhematologicalmalignancies AT panwanying preclinicalandclinicaladvancesindualtargetchimericantigenreceptortherapyforhematologicalmalignancies AT changning preclinicalandclinicaladvancesindualtargetchimericantigenreceptortherapyforhematologicalmalignancies AT zhouxuan preclinicalandclinicaladvancesindualtargetchimericantigenreceptortherapyforhematologicalmalignancies AT songchaoyang preclinicalandclinicaladvancesindualtargetchimericantigenreceptortherapyforhematologicalmalignancies AT liyuhua preclinicalandclinicaladvancesindualtargetchimericantigenreceptortherapyforhematologicalmalignancies AT heyanjie preclinicalandclinicaladvancesindualtargetchimericantigenreceptortherapyforhematologicalmalignancies |